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Introduction. Brachytherapy has evolved from the traditional surgical paradigm to modern three-dimensional image-based plan-
ning and delivery approaches.
Objectives. To analyse the international recommendations in brachytherapy quality assurance (QA) and the situation in Spain.
Materials and methods. We have reviewed international recommendations and the Spanish reality regarding brachytherapy QA.
In all international documents about brachytherapy QA there is a distinction between QA device (periodic testing of planning,
delivery and imaging systems) and QA clinical process (patient-speciﬁc treatment procedures). Different proactive tools are used
for a QA analysis, being the more used the failure mode and effect analysis (FMEA). It has three steps: ﬁrst, generate an overview
of the entire process (process map), in which all the nodes of the brachytherapy process are represented. Second, identify possible
failure nodes in every part of the process. Third, develop process improvements lowering the overall risk for each failure node.
The current Spanish RD1566/1998 (Quality Criteria in Radiotherapy), RD815/2001 (Justiﬁcation of medical exposure to ionizing
radiation) and Libro Blanco SEORXXI, deal with this subject.
Results. Available brachytherapy QA international recommendations are relatively ﬁxed protocols of speciﬁc tests, endpoints,
tolerances and frequencies that have been developed by small panels of experts and reﬂect practice patterns that predate the
image-based planning era. There is not unanimity in QA guidance. In our country there is no document/guide for brachytherapy
QA. Spanish RD do not include speciﬁc recommendations. There are mandatory legal regulations for radiotherapy procedures in
Spain with a punitive character. The Libro Blanco reﬂects the lack of studies and recommendations in brachytherapy QA.
Conclusions. Due to the complexity and variability of image-based brachytherapy procedures, a risk-based guide including clear
general QA protocols guidelines for the speciﬁc clinical implementations, is urgently needed.
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Purpose. To analyze the results of HDR brachytherapy (HDRBT) administered daily on local control and toxicity in postoperative
endometrial carcinoma (EC).
Materials and methods. From January 2007 to September 2010, 112 patients with FIGO Stage 24-IA, 48-IB, 14-II, 12-IIIA, II-IIIB, 8-IIIC1
and 4-IIIC2, were treated with HDRBT after surgery. Pathology: 99/112 endometrioid and 23/112 other types. Radiotherapy (two
groups of patients): Group 1: 70/112 external beam irradiation (EBI) +HDRBT (2 fractions 5–6Gy); Group 2: 42/112 HDRBT alone (4
fractions 5–6Gy). Toxicity evaluation: RTOG scores for bladder and rectum; objective criteria of LENT-SOMA for vagina.
Statistics. Chi-square and Fisher exact test.
Results. With a mean follow-up of 37 months (range 9.6–79.3) one patient developed vaginal-cuff relapse after 11 months (Group
1). Toxicity. Group 1: early G1–G2 appeared in 9% in rectum, 8.3% bladder, 1.4% in vagina; late problems appeared in 8.5% in
rectum (all G1–2 but 2 G3) and 29.1% in vagina (all G1–2 but 1 G4). Group 2: Early G1–2 toxicity 9.4% in bladder, 6.9% in vagina; late
problems only appeared in 23.8% in vagina (G1–2).
Conclusions. Daily HDRBT using 2 fractions of 5Gy after EBI and 4 fractions of 5Gy as exclusive treatment was a safe regime in
terms of local control and toxicity. Group 1 had a higher incidence of late vaginal, rectal and bladder toxicity than group 2. In
patients treated with HDRBT alone only G1–G2 late vagina toxicity was observed.
http://dx.doi.org/10.1016/j.rpor.2013.03.709
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Background. Lip carcinoma has been successfully treated with LDR brachytherapy. High-dose-rate brachytherapy (HDR-BT) publi-
cations are scarce andwith short follow-up.Weanalyze the results andprognostic factors in invasive squamous-cell lip carcinoma
with HDR.
